Biotech IPOs Took the Week, Led by Braveheart and Latigo

Biotech issuers controlled the U.S. IPO tape in the week ended August 9, and the strongest deals did more than get through. Braveheart Bio priced above its range, Latigo Biotherapeutics landed at the top, Attovia Therapeutics enlarged its offering, and BlossomHill Therapeutics reached the midpoint. Together, the four companies sold about $1.17 billion of stock before underwriter options, a concentrated reopening for clinical-stage risk.

The demand signal was selective. Investors paid up for large, specialist-led offerings tied to programs with identifiable clinical milestones. Smaller deals had less leverage: Ticketplus priced at the bottom of a range that had already been cut sharply. IPOGrid reads the week as evidence that healthcare books can absorb real size, while still forcing weaker or less familiar issuers to concede on price.

Braveheart set the high-water mark

Braveheart Bio delivered the clearest pricing win. The cardiovascular drug developer sold 21.25 million shares at $18, above its $15 to $17 range, for $382.5 million in gross proceeds. The final size was also larger than the 18.75 million shares contemplated before pricing, according to contemporaneous deal coverage. Goldman Sachs, Jefferies, TD Cowen, Stifel and Cantor were listed on the final prospectus.

The scale reflects the capital requirement. Braveheart is advancing BHB-1893, an oral cardiac myosin inhibitor licensed from Jiangsu Hengrui, for hypertrophic cardiomyopathy. Its registration statement shows $10.9 million of research and development expense in the first quarter, including a $6 million Hengrui milestone and spending to start the obstructive HCM Phase 3 study. Our interpretation is that investors funded a late-stage cardiovascular program and an experienced syndicate, while accepting concentrated clinical and licensing risk. Pricing strength does not diversify the pipeline.

Latigo raised late-stage pain capital

Latigo followed with 19.2 million shares at $18, the top of its $16 to $18 range, for $345.6 million. Goldman Sachs, Jefferies, Leerink Partners and Guggenheim led the offering. The deal gives Latigo substantial funding for LTG-001, its oral NaV1.8 inhibitor for acute pain, including planned late-stage studies. The company’s earlier filing described the program as a non-opioid approach, and Fierce Biotech reported that proceeds were intended in part for a Phase 3 bunion-surgery study and another broader late-stage trial.

Latigo’s terms were strong without the premium achieved by Braveheart. IPOGrid reads that difference as sensible. NaV1.8 is a validated commercial target, which helps frame the opportunity, but it also gives public investors a visible comparator and a higher bar for differentiation. The financing buys clinical runway. It does not settle efficacy, safety, or competitive positioning.

Attovia won on size, BlossomHill held the middle

Attovia produced the week’s sharpest size revision. It sold 17 million shares at $17, the top of its $15 to $17 range, after initially planning 12.5 million shares. That lifted gross proceeds to $289 million, versus roughly $268.8 million of estimated proceeds after underwriting discounts and offering costs in the final prospectus. Deal reporting confirmed the increase. Morgan Stanley, Leerink, Citi and RBC anchored the book, with LifeSci also participating.

Attovia is developing ATTO-1310, an IL-31-targeting biologic built on its licensed ATTOBODY platform. The initial filing says Phase 1 dosing in healthy volunteers and patients was completed in the first quarter. The reviewer’s concern is straightforward: the company entered the market with early clinical evidence and a competitive immunology target. The upsized book is encouraging financing evidence, not clinical validation.

BlossomHill’s outcome was more conventional. The oncology company sold 9.375 million shares at $16, the midpoint of its $15 to $17 range, raising $150 million. J.P. Morgan, Leerink and Guggenheim led the final deal, with LifeSci and H.C. Wainwright in the syndicate. Its pipeline focuses on small molecules intended to address cancer-treatment resistance, with the company identifying a late-2026 regulatory meeting among the next milestones for its C797S program. Midpoint pricing and a high-quality bookrunner group amount to a clean execution, though the terms do not show the same demand pressure visible in Braveheart or Attovia.

The smaller end still paid for access

Ticketplus supplied the counterpoint. The Chilean ticketing platform sold 1.875 million shares at $8 for $15 million, at the bottom of its latest $8 to $10 range. Earlier in July it had sought 1.786 million shares at $13 to $15, according to coverage of the prior terms. Its final prospectus shows a much smaller capital raise than the biotech cohort. We would frame that reset as the week’s clearest caution flag: completion required a materially lower valuation entry point.

Next up, Londian Wason New Energy Tech moved closer to market with 3.57 million ADSs indicated at $20 to $22, or roughly $75 million at the midpoint. Its amended prospectus disclosed indications of interest totaling as much as $87 million from Harvest Global Capital, Hithium Global and other investors. Those indications are nonbinding, so IPOGrid treats them as book support rather than completed demand. Still, the copper-foil producer gives the next calendar a larger industrial test after a week dominated by drug developers.

The week mattered because the strongest healthcare issuers converted ambitious terms into sizable financings. The follow-through question is now clinical and trading durability. Braveheart, Latigo and Attovia have capital; public investors still need their programs to earn the valuations that the primary market supplied.